Shkreli commits to 'modest' price reduction for Daraprim

Turing Pharmaceuticals AG (New York, N.Y.) CEO Martin Shkreli said in an interview with HIV activist Josh Robbins the company will commit to a "modest" price reduction of about 10% for toxoplasmosis drug Daraprim pyrimethamine by year end. Shkreli also said he is considering discounts on the order of 25-50% for smaller hospitals that cannot afford to stock Daraprim.

A Turing spokesperson told BioCentury further discussions on Daraprim discounts are "premature." ...